Why are leukocyte-reduced blood products preferred in transfusions?

Leukocyte-reduced blood products are preferred in transfusions primarily because they significantly reduce the risk of febrile non-hemolytic reactions. These reactions can occur when the immune system reacts to white blood cells (leukocytes) present in the transfused blood. By using leukocyte-reduced blood products, which have most of the white blood cells removed, the likelihood of such reactions occurring is minimized. This can lead to better patient outcomes, as patients can tolerate transfusions more easily without experiencing these fevers or chills that can be caused by the immune response to leukocytes.

In the context of blood transfusions, the removal of leukocytes not only enhances the safety of the transfusion but also makes the process smoother for patients, allowing healthcare providers to focus on the primary goals of the transfusion without the complications that can arise from these reactions.